TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00693498

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard leukoreduced irradiated blood cell transfusion
Description: standard vs washed blood cell transfusions

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Washed leukoreduced irradiated blood cell transfusions
Description: washed leukoreduced irradiated blood cell transfusions
Study: NCT03625765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartGoggles
Description: the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
Study: NCT01259804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Daily doses of peanut flour
Study: NCT02844699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilan (M-VM3)
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilan (M-VM3)
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% infusion solution of dextrose (glucose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% infusion solution of dextrose (glucose)
Study: NCT03757221

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ixazomib and Daratumumab
Description: Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment.
Study: NCT03520400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
Study: NCT03375502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: The subject will receive investigational product or comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: The subject will receive investigational product or comparator.
Study: NCT04686786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865
Description: Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
Study: NCT03534310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle modification

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Study: NCT03034343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study: NCT02323984

Intervention type: OTHER
Intervention: miRNA Testing, Microemboli Monitoring, Delirium Assessment
Description: Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).

Intervention type: OTHER
Intervention: miRNA Testing, Microemboli Monitoring, Delirium Assessment
Description: Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).

Intervention type: OTHER
Intervention: miRNA Testing, Microemboli Monitoring, Delirium Assessment
Description: Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
Study: NCT02464800

Intervention type: PROCEDURE
Intervention: Vitrectomy for proliferative diabetic retinopathy
Description: 25-gauge vitrectomy

Intervention type: PROCEDURE
Intervention: Vitrectomy for proliferative diabetic retinopathy
Description: 25-gauge vitrectomy
Study: NCT01622244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-ordinated Access to Care from Hospital Emergency Departments
Description: brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
Study: NCT01598233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Intragastric balloon
Description: Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
Study: NCT03195725

Intervention type: OTHER
Intervention: Review of notes
Description: No intervention will occur

Intervention type: OTHER
Intervention: Review of notes
Description: No intervention will occur
Study: NCT01622244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Access to Care from Hospital Emergency Departments
Description: Participants will receive brief, intensive case management to connect them to health and social services and supports in the community

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and Resource Education
Description: Participants will receive usual care as well as an educational session and resource guide outlining community-based services
Study: NCT02347657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661 Plus Ivacaftor Combination
Description: FDC tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-661 Plus Ivacaftor Combination Placebo
Description: FDC tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor placebo
Description: Tablet, oral use
Study: NCT01455207

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: assessment of memory, executive functions and ataxia

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: assessment of memory, executive functions and ataxia

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: assessment of memory, executive functions and ataxia

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood draw
Description: hepatic markers, red blood markers and vitamin markers

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood draw
Description: hepatic markers, red blood markers and vitamin markers

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood draw
Description: hepatic markers, red blood markers and vitamin markers

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic testing
Description: genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
Study: NCT04103905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62 Injection
Description: The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
Study: NCT01455207

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic testing
Description: genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic testing
Description: genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging examination
Description: MRI, DTI and PET examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging examination
Description: MRI, DTI and PET examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging examination
Description: MRI, DTI and PET examinations
Study: NCT04482543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
Study: NCT03883516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-briefing with the current SE treatment guidelines
Description: instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-briefing with a consolidated one page SE treatment guide
Description: instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Pre-briefing
Description: no instruction of the study participants prior to the simulation training
Study: NCT03469284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care therapy
Study: NCT01520285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanidip
Description: Lercanidipine hydrochloride (10mg/tablet)once per day
Study: NCT01891513

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.

Intervention type: DRUG
Intervention: ACE inhibitor + exercise
Description: In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.

Intervention type: DRUG
Intervention: Thiazide diuretic + exercise
Description: In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.

Intervention type: DRUG
Intervention: Angiotensin receptor blocker + exercise
Description: In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
Study: NCT01399723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral 45mg/kg 12 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: Intravenous 50,000IU/kg 6 hourly
Study: NCT01520285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Felodipine sustained-release tablet
Description: Felodipine sustained-release tablet (5mg/tablet)
Study: NCT01695525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
Study: NCT03469284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care therapy
Study: NCT01976650

Intervention type: DRUG
Intervention: dexamethasone 700 ㎍ intravitreal implant
Description: dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
Study: NCT03469284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given lower dose PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given medium dose PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given higher dose PO
Study: NCT02447289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ketamine
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
Study: NCT02132598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Study: NCT05046652

Intervention type: BIOLOGICAL
Intervention: Convalescent Plasma Therapy
Description: In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
Study: NCT04506255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone tape
Description: Medical grade tape with silicone adhesive
Study: NCT02515565

Intervention type: DRUG
Group type: OTHER
Intervention: cephalosporin with or without erythromycin
Description: Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Description: The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
Study: NCT03135665

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral.
Study: NCT03841097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Tacrolimus Tablets
Description: The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Tacrolimus Capsule
Description: The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
Study: NCT02492958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus 4-antigen vaccine
Description: a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
Study: NCT01412138

Intervention type: OTHER
Intervention: genetic analysis
Description: 1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group.
Study: NCT04113655

Intervention type: BIOLOGICAL
Intervention: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
Study: NCT04464135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetic acid staining
Description: The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange colonoscopy
Description: The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
Study: NCT00672854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic 20% Intravenous Emulsion
Description: ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
Study: NCT04113655

Intervention type: BIOLOGICAL
Intervention: Boostagen (TdaP BioNet)
Description: Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.

Intervention type: BIOLOGICAL
Intervention: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202
Study: NCT04092725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAB
Description: Single oral 150-mg dose of DAB on Day 1 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078 plus DAB
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
Study: NCT04751422

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical data is collected
Study: NCT02380222

Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour

Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour

Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour

Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour

Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour